{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:14:47Z","timestamp":1791832487831,"version":"4.3.4"},"reference-count":99,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Invasive meningococcal disease (IMD) is an uncommon but potentially life-threatening condition, resulting in life-long sequelae or death in up to 20% of cases. Most IMD cases are caused by Neisseria meningitidis serogroups (Men) A, B, C, W, X, and Y. The highest IMD incidence is among children &lt; 5 years of age (YOA). We reviewed IMD epidemiology data and existing national immunization programs (NIP) in the Americas and identify unmet needs to decrease IMD burden in young children. Methods: Using national surveillance data and published literature from 2006 to 2024, we evaluated the IMD burden and national vaccination strategies for children &lt; 5 YOA in the Americas, focusing on Canada, the United States, Brazil, Chile, Argentina. Results: The highest IMD incidence was among infants, followed by children 1\u20134 YOA, with MenB infections predominating in both age groups. Chile has both MenACWY (2014) and MenB (2023) infant vaccination in its NIP. Argentina and Brazil\u2019s NIPs include MenACWY (2017) and MenC (2010) vaccinations for infants, respectively. In Canada, MenC (2002) vaccination is recommended at 1 YOA (replaced by MenACWY in 2024 in Manitoba); MenB vaccination is selectively recommended. In each country, the incidence of IMD caused by vaccine-preventable serogroups decreased following the introduction of the respective meningococcal vaccination in the NIP. Conclusions: Comprehensive meningococcal vaccination programs in the Americas have the potential to reduce the IMD burden in children &lt; 5 YOA. National recommendations and NIPs could reduce IMD burden by offering equitable access to protection against IMD, aligning with the WHO roadmap to defeat meningitis by 2030.<\/jats:p>","DOI":"10.3390\/vaccines13090974","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:56:46Z","timestamp":1758013006000},"page":"974","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas"],"prefix":"10.3390","volume":"13","author":[{"given":"Gaurav","family":"Mathur","sequence":"first","affiliation":[{"name":"GSK, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Domachowske","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela","family":"Gra\u00f1a","sequence":"additional","affiliation":[{"name":"GSK, Recoleta 8431633, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Ladak","sequence":"additional","affiliation":[{"name":"GSK, Singapore 139234, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3270-7345","authenticated-orcid":false,"given":"Joanne M.","family":"Langley","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Departments of Pediatrics and Community Health and Epidemiology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, NS B3K 6R8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5049-0111","authenticated-orcid":false,"given":"Oluwatosin","family":"Olaiya","sequence":"additional","affiliation":[{"name":"GSK, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-8903","authenticated-orcid":false,"given":"Alysa","family":"Pompeo","sequence":"additional","affiliation":[{"name":"GSK, Toronto, ON L5R 4B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Taddei","sequence":"additional","affiliation":[{"name":"GSK, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-1387","authenticated-orcid":false,"given":"Rodolfo","family":"Villena","sequence":"additional","affiliation":[{"name":"Hospital Dr. Exequiel Gonz\u00e1lez Cort\u00e9s, Santiago 8900000, Chile"},{"name":"Faculty of Medicine, Universidad de Chile, Santiago 1058, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements","volume":"59","year":"2016","journal-title":"J. Adolesc. Health"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Shen, J., Begum, N., Ruiz-Garcia, Y., Martinon-Torres, F., Bekkat-Berkani, R., and Meszaros, K. (2022). Range of invasive meningococcal disease sequelae and health economic application\u2014A systematic and clinical review. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-13342-2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/21645515.2018.1451810","article-title":"Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development","volume":"14","author":"Dretler","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s41999-024-00969-0","article-title":"Invasive meningococcal disease in older adults: Current perspectives and call for action","volume":"15","author":"Taha","year":"2024","journal-title":"Eur. Geriatr. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: A literature review","volume":"151","author":"Findlow","year":"2023","journal-title":"Epidemiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","article-title":"Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations","volume":"116","author":"Taha","year":"2022","journal-title":"Pathog. Glob. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s40121-024-01063-5","article-title":"Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review","volume":"13","author":"Shen","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s40121-023-00886-y","article-title":"Epidemiology of Invasive Meningococcal Disease in Colombia: A Retrospective Surveillance Database Analysis","volume":"12","author":"Caceres","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.14745\/ccdr.v40i09a01","article-title":"Enhanced surveillance of invasive meningococcal disease in Canada, 2006\u20132011","volume":"40","author":"Li","year":"2014","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2237391","DOI":"10.1080\/21645515.2023.2237391","article-title":"Meningococcal burden of disease in Argentina: 10 years epidemiologic review","volume":"19","author":"Neyro","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.14745\/ccdr.v48i05a06","article-title":"Epidemiology of invasive meningococcal disease in Canada, 2012\u20132019","volume":"48","author":"Saboui","year":"2022","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Villena, R., Safadi, M.A., Gentile, \u00c1., Pujadas, M., De la Maza, V., George, S., and Torres, J.P. (2023). Epidemiology of Meningococcal Disease in Four South American Countries and Rationale of Vaccination in Adolescents from the Region: Position Paper of the Latin American Society of Pediatric Infectious Diseases (SLIPE). Vaccines, 11.","DOI":"10.3390\/vaccines11121841"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1016\/j.vaccine.2019.09.050","article-title":"Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile","volume":"37","author":"Villena","year":"2019","journal-title":"Vaccine"},{"key":"ref_16","unstructured":"Government of Canada (2025, May 05). Invasive Meningococcal Disease: Monitoring. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/invasive-meningococcal\/monitoring.html."},{"key":"ref_17","first-page":"1","article-title":"Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005","volume":"33","author":"Li","year":"2007","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_18","unstructured":"Government of Canada (2024, July 15). Meningococcal Vaccines: Canadian Immunization Guide. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-13-meningococcal-vaccine.html#p4c12a5."},{"key":"ref_19","unstructured":"Ministry of Health Brazil (2024, December 16). Epidemiological Panel: Meningitis. Meningococcal Disease. Available online: https:\/\/app.powerbi.com\/view?r=eyJrIjoiODBkZTAyNDUtOTNhYi00NjQ2LWJmMjEtMjUwMDMxNDQzMzI5IiwidCI6IjlhNTU0YWQzLWI1MmItNDg2Mi1hMzZmLTg0ZDg5MWU1YzcwNSJ9."},{"key":"ref_20","unstructured":"Direcci\u00f3n de Epidemiolog\u00eda Ministerio de Salud de la Naci\u00f3n (2024, July 15). Argentina. Bolet\u00edn Epidemiol\u00f3gico Nacional. N\u00b0 657, SE 23, A\u00f1o 2023. Informes Especiales, Available online: https:\/\/www.argentina.gob.ar\/sites\/default\/files\/2024\/04\/ben_657_se_23.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14745\/ccdr.v49i09a01","article-title":"A National Advisory Committee on Immunization (NACI) update on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure","volume":"49","author":"Zafack","year":"2023","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_22","unstructured":"(2025, March 10). Publicly Funded Immunization Schedules for Ontario, 2022, Available online: https:\/\/health.gov.on.ca\/en\/pro\/programs\/immunization\/schedule.aspx."},{"key":"ref_23","unstructured":"Centers for Disease Control and Prevention (2025, March 04). Child Immunization Schedule Notes. Recommendations for Ages 18 Years or Younger, United States, 2025, Available online: https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html."},{"key":"ref_24","unstructured":"World Health Organization (2025, March 04). Vaccination Schedule for Meningococcal Disease: Brazil. Available online: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/vaccination-schedule-for-meningococcal-disease?ISO_3_CODE=BRA&TARGETPOP_GENERAL=."},{"key":"ref_25","unstructured":"Ministerio de Salud Chile (2025, March 04). Recomendaciones Para la Vacunaci\u00f3n de Pacientes con Necesidades Especiales por Patolog\u00edas o Situaciones de Riesgo. Available online: https:\/\/www.sochinf.cl\/portal\/templates\/sochinf2008\/documentos\/2019\/MANUAL_VACUNAS_ESPECIALES.pdf."},{"key":"ref_26","unstructured":"Ministerio de Salud Argentina (2025, March 04). Hu\u00e9spedes Especiales: Estrategia de Vacunaci\u00f3n Contra Meningococo de Argentina, Available online: https:\/\/www.argentina.gob.ar\/sites\/default\/files\/bancos\/2020-10\/huespedes-especiales-estrategia-de-vacunacion-contra-meningococo-de-argentina.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s40121-021-00499-3","article-title":"Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination","volume":"10","author":"Soumahoro","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine","volume":"292","author":"Deceuninck","year":"2004","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3201\/eid0805.010337","article-title":"Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada","volume":"8","author":"Tyrrell","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada","volume":"64","author":"Deceuninck","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106163","DOI":"10.1016\/j.jinf.2024.106163","article-title":"Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex","volume":"88","author":"Tsang","year":"2024","journal-title":"J. Infect."},{"key":"ref_33","unstructured":"Dalhousie University (2025, May 05). Public Health Investigating Two Cases of Meningococcal Disease at Dalhousie University, Death of One Student. Available online: https:\/\/www.dal.ca\/news\/2022\/12\/16\/public-health-investigating-two-cases-of-meningococcal-disease-a.html."},{"key":"ref_34","unstructured":"Manitoba Health (2024, July 15). Meningococcal Disease (Neisseria meningitidis), Available online: https:\/\/www.gov.mb.ca\/health\/publichealth\/diseases\/meningococcus.html."},{"key":"ref_35","unstructured":"Centers for Disease Control and Prevention (2024, July 10). Meningococcal Disease Surveillance and Trends, Available online: https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html."},{"key":"ref_36","unstructured":"Centers for Disease Control and Prevention (2025, February 27). National Notifiable Diseases Surveillance System (NNDSS), Available online: https:\/\/www.cdc.gov\/nndss\/infectious-disease\/index.html."},{"key":"ref_37","unstructured":"Centers for Disease Control and Prevention (2025, May 09). Enhanced Meningococcal Disease Surveillance Report, 2023, Available online: https:\/\/www.cdc.gov\/meningococcal\/media\/pdfs\/2025\/04\/NCIRD-EMDS-Report-2023_508.pdf."},{"key":"ref_38","unstructured":"Orenstein, W., Offit, P., Edwards, K.M., and Plotkin, S. (2023). Chapter 40\u2014Meningococcal Vaccines Directed at Capsular Group B. Plotkin\u2019s Vaccines, Elsevier. [8th ed.]."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013\u20132018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_41","unstructured":"Rubis, A. (2025, May 09). Epidemiology of Meningococcal Disease in the United States. United States Advisory Committee on Immunization Practices Meeting 2024 June 26\u201328, Atlanta, GA, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/157878."},{"key":"ref_42","unstructured":"Centers for Disease Control and Prevention (2024, July 11). Increase in Invasive Serogroup Y Meningococcal Disease in the United States, Available online: https:\/\/emergency.cdc.gov\/han\/2024\/han00505.asp."},{"key":"ref_43","unstructured":"Centers for Disease Control and Prevention (2025, March 10). Child and Adolescent Immunization Schedule by Age, Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-age.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html."},{"key":"ref_44","unstructured":"Hospital do Servidor P\u00fablico Municipal S\u00e3o Paulo (2025, May 09). \u201cAs Pessoas N\u00e3o Est\u00e3o se Vacinando\u201d: Surto de Meningite Alerta Paulistanos, Available online: https:\/\/capital.sp.gov.br\/web\/hospital_do_servidor_publico_municipal\/w\/noticias\/338513."},{"key":"ref_45","unstructured":"CVP Vacinas (2025, March 02). Surto de Meningite Meningoc\u00f3cica B em Alagoas: Letalidade de Quase 50%. Available online: https:\/\/cvpvacinas.com.br\/2023\/11\/17\/surto-de-meningite-meningococica-b-em-alagoas-letalidade-de-quase-50\/."},{"key":"ref_46","unstructured":"Ag\u00eancia Brasil (2025, May 09). Rio Registra Aumento de Casos e \u00d3bitos por Meningite Meningoc\u00f3cica. Available online: https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-11\/rio-registra-aumento-de-casos-e-obitos-por-meningite-meningococica."},{"key":"ref_47","unstructured":"Instituto de Salud Publica\u2014Ministerio de Salud Chile (2025, March 10). Bacterologia\u2014Informes de Resultados, Available online: https:\/\/www.ispch.gob.cl\/andim\/gestion-de-la-informacion\/vigilancia-laboratorios-de-agentes-infecciosos\/bacterologia-informes-de-resultados\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4067\/S0716-10182014000400001","article-title":"Vigilancia de laboratorio de enfermedad meningoc\u00f3ccica invasora en Chile, 2006\u20132012","volume":"31","author":"Araya","year":"2014","journal-title":"Rev. Chil. De Infectolog\u00eda"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4067\/S0370-41062012000600002","article-title":"Historia y epidemiolog\u00eda del meningococo","volume":"83","author":"Wilhelm","year":"2012","journal-title":"Rev. Chil. De Pediatr\u00eda"},{"key":"ref_50","unstructured":"Ministerio de Salud Chile, Subsecretaria de Salud Publica, Departamento de Epidemiologia (2024, July 11). Ord. B51 No. 1659 Envia Alerta Epidemiologica Vigilancia Enf. Meningococica por Aumento Estacional Esperado Meses de Invierno-2024. Available online: https:\/\/epi.minsal.cl\/alertas-epidemiologicas-vigentes\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4067\/S0034-98872013000800001","article-title":"Emergence of W135 meningococcal serogroup in Chile during 2012","volume":"141","author":"Valenzuela","year":"2013","journal-title":"Rev. Med. Chil."},{"key":"ref_52","unstructured":"Ministerio de Salud Chile (2025, March 10). Ministerio de Salud Incorpora Dosis de Refuerzo de la Vacuna Meningoc\u00f3cica Recombinante Serogrupo B. Available online: https:\/\/serviciodesaludnuble.cl\/portal\/vacuna-bexsero-refuerza-la-proteccion-contra-la-meningitis-b-en-chile-en-ninas-y-ninos-de-18-meses\/."},{"key":"ref_53","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2006. Available online: https:\/\/www.paho.org\/es\/documentos\/informe-regional-sireva-ii-2006."},{"key":"ref_54","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2007. Available online: https:\/\/www3.paho.org\/hq\/dmdocuments\/2009\/SirevaII2007.pdf."},{"key":"ref_55","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2008. Available online: https:\/\/www3.paho.org\/hq\/dmdocuments\/2012\/Informe-Regional-SIREVAII-2008.pdf."},{"key":"ref_56","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2009. Available online: https:\/\/www3.paho.org\/hq\/dmdocuments\/2010\/SIREVA%20II%202009.pdf."},{"key":"ref_57","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2010. Available online: https:\/\/www3.paho.org\/hq\/dmdocuments\/2011\/SIREVA-II-2010.pdf."},{"key":"ref_58","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2011. Available online: https:\/\/www3.paho.org\/hq\/dmdocuments\/2012\/SIREVA-II-2011-Sp.pdf."},{"key":"ref_59","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2012. Available online: https:\/\/www3.paho.org\/hq\/index.php?option=com_docman&view=download&alias=30766-informe-regional-sireva-ii-2012-766&category_slug=sireva-ii-8059&Itemid=270&lang=pt."},{"key":"ref_60","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2013. Available online: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/31147\/9789275319185-spa.pdf?sequence=5&isAllowed=y."},{"key":"ref_61","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2014. Available online: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/33875\/9789275319420-spa.pdf?sequence=1&isAllowed=y."},{"key":"ref_62","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2015. Available online: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/49091\/9789275320099_spa.pdf?sequence=1&isAllowed=y."},{"key":"ref_63","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2016. Available online: https:\/\/iris.paho.org\/handle\/10665.2\/51781."},{"key":"ref_64","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2017. Available online: https:\/\/iris.paho.org\/handle\/10665.2\/53136."},{"key":"ref_65","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, July 15). Informe Regional de SIREVA II, 2018. Available online: https:\/\/iris.paho.org\/handle\/10665.2\/54567."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0950268814001149","article-title":"Serogroup W meningococcal disease: Global spread and current affect on the Southern Cone in Latin America","volume":"142","author":"Abad","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"ref_67","first-page":"8","article-title":"Invasive Meningococcal Disease. Cuba, 1983\u20132006","volume":"19","author":"Dickinson","year":"2010","journal-title":"Vaccimonitor"},{"key":"ref_68","first-page":"31","article-title":"Vacuna cubana antimeningoc\u00f3cica VA-MENGOC-BC\u00ae: Treinta a\u00f1os de uso y potencialidades vigentes","volume":"29","year":"2020","journal-title":"Vaccimonitor"},{"key":"ref_69","unstructured":"World Health Organization (2024, July 15). Invasive Meningococcal Disease Reported Cases and Incidence. Available online: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/invasive-meningococcal-disease-reported-cases-and-incidence?CODE=CRI&YEAR=."},{"key":"ref_70","first-page":"2","article-title":"Vigilancia de las infecciones por Neisseria meningitidis Costa Rica 1998\u20132001","volume":"14","author":"Chanto","year":"2002","journal-title":"Boletin Inciensa"},{"key":"ref_71","unstructured":"Centro Nacional de Referencia de Bacteriolog\u00eda (2024, July 11). Informe de Vigilancia Basada en Laboratorio: Neisseria meningitidis, Costa Rica, 2006\u20132015. Available online: https:\/\/www.inciensa.sa.cr\/wp-content\/uploads\/simple-file-list\/Informes-Epidemiologicos\/2016\/Bacterias\/Vigilancia-de-laboratorio-de-Neisseria-meningitidis-Costa-Rica-2006-2015.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2022.10.022","article-title":"Meningococcal disease in North America: Updates from the Global Meningococcal Initiative","volume":"85","author":"Asturias","year":"2022","journal-title":"J. Infect."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S1020-49892008000700001","article-title":"Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000\u20132005","volume":"24","author":"Gabastou","year":"2008","journal-title":"Rev. Panam. Salud Publica"},{"key":"ref_74","unstructured":"Ministerio de Salud Panama (2025, March 10). Direccion General de Salud Publica, Departamento Nacional de Epidemiologia. Boletin Epidemiologico Semanal. Semana 51, Available online: https:\/\/www.minsa.gob.pa\/sites\/default\/files\/publicacion-general\/boletin_epidemiologico_semanal_se_51_0.pdf."},{"key":"ref_75","first-page":"19","article-title":"Epidemiolog\u00eda de la enfermedad por meningococo en Colombia","volume":"21","year":"2017","journal-title":"Infectio"},{"key":"ref_76","unstructured":"Ministerio de Salud P\u00fablica Uruguay (2025, March 02). Aumento de Casos de Enfermedad Meningoc\u00f3cica. Available online: https:\/\/www.gub.uy\/ministerio-salud-publica\/comunicacion\/comunicados\/aumento-casos-enfermedad-meningococica."},{"key":"ref_77","unstructured":"Comisi\u00f3n Nacional Asesora de Vacunaciones (CNAV) Uruguay (2024, July 15). Acta Reuni\u00f3n CNAV 2\/10\/2024. Available online: https:\/\/www.gub.uy\/ministerio-salud-publica\/sites\/ministerio-salud-publica\/files\/documentos\/publicaciones\/CNAV%202%20octubre%202024.pdf."},{"key":"ref_78","unstructured":"World Health Organization (2025, March 04). Defeating Meningitis by 2030: A Global Road Map. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240026407."},{"key":"ref_79","unstructured":"World Health Organization (2025, March 04). Meningococcal Disease. Vaccine and Vaccination. Available online: https:\/\/www.emro.who.int\/health-topics\/meningococcal-disease\/vaccine-vaccination.html#:~:text=Conjugate%2520meningococcal%2520vaccine,who%2520have%2520had%2520meningococcal%2520disease."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2186111","DOI":"10.1080\/21645515.2023.2186111","article-title":"Changing patterns of invasive meningococcal disease and future immunization strategies","volume":"19","author":"Taha","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2357924","DOI":"10.1080\/21645515.2024.2357924","article-title":"4CMenB journey to the 10-year anniversary and beyond","volume":"20","author":"Abitbol","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme\u2014New challenges for public health","volume":"71","author":"Ladhani","year":"2015","journal-title":"J. Infect."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","article-title":"The important lessons lurking in the history of meningococcal epidemiology","volume":"23","author":"Borrow","year":"2024","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: Analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s40121-023-00888-w","article-title":"Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare","volume":"12","author":"Bloom","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jinf.2023.09.002","article-title":"Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England","volume":"87","author":"Clark","year":"2023","journal-title":"J. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Findlow, J., Htar, M.T.T., Villena, R., and Balmer, P. (2025). Invasive Meningococcal Disease in the Post-COVID World: Patterns of Disease Rebound. Vaccines, 13.","DOI":"10.3390\/vaccines13020165"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","first-page":"1","article-title":"Childhood vaccine coverage in Italy after the new law on mandatory immunization","volume":"30","author":"Signorelli","year":"2018","journal-title":"Ann. Ig."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Azzari, C., Moriondo, M., Nieddu, F., Guarnieri, V., Lodi, L., Canessa, C., Indolfi, G., Giovannini, M., Napoletano, G., and Russo, F. (2020). Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014\u20132018). Vaccines, 8.","DOI":"10.3390\/vaccines8030469"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2333106","DOI":"10.1080\/21645515.2024.2333106","article-title":"Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals","volume":"20","author":"Bonanni","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000930","article-title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration","volume":"35","author":"Gasparini","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2245705","DOI":"10.1080\/21645515.2023.2245705","article-title":"Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review","volume":"19","author":"Abitbol","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England","volume":"38","author":"Beck","year":"2020","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: Targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"126589","DOI":"10.1016\/j.vaccine.2024.126589","article-title":"Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina","volume":"45","author":"Pannunzio","year":"2025","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14760584.2022.2052048","article-title":"Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease","volume":"21","author":"Taha","year":"2022","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","article-title":"Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease","volume":"24","author":"Beck","year":"2021","journal-title":"Value Health"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/974\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:04Z","timestamp":1760035504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":99,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090974"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090974","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]}}}